Pibrentasvir is used in the treatment of chronic hepatitis C virus (HCV) infection. It works by inhibiting the NS5A protein of the virus, which is essential for viral replication and assembly. It is typically combined with another antiviral agent, glecaprevir, to form a direct-acting antiviral regimen. This combination is effective across multiple HCV genotypes and is prescribed for both treatment-naive and experienced patients, including those with compensated cirrhosis. The therapy offers high cure rates, usually within 8 to 12 weeks, and is known for its favorable side effect profile and minimal drug interactions. It plays a key role in reducing liver damage, preventing progression to cirrhosis or liver cancer, and decreasing HCV transmission.